BrandMemo | manage and share brands you love  Pharmamedix su Facebook  Pharmamedix su Twitter
 Home | News | About us | Comitato scientifico | Iscriviti | Utenti | Etica | Contenuti | Guida | Faq | Stage | Contatti
Logo Pharmamedix
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Metformina

Metforal, Glibomet, Competact e altri

Bibliografia - Quali fonti bibliografiche per Metformina?


         
  1. Agenzia Italiana del Farmaco – AIFA, Vokanamet – Riassunto Caratteristiche di Prodotto, 2014, 22 maggio disponibile online https://farmaci.agenziafarmaco.gov.it/bancadatifarmaci

  2. Althoff P-H. et al., Diabets, 1991, 40 Suppl. 1, 342.

  3. Andrès E. et al., Arch. Intern. Med., 2000, 160 (13), 2061.

  4. Bailey C.J., Diabetes Metab. Rev., 1995, 11 Suppl. 1, S23.

  5. Bailey C.J., Turner RC, NEJM, 1996, 334 (9), 574.

  6. Ben Salem C. et al., Ann. Pharmacother., 2006, 40 (9), 1685.

  7. Blandino G. et al., Net. Comun., 2012, 29 (3), 865.

  8. Briggs GG. et al., Philadelphia, Pa: Lippincott, Williams and Wilkins; 2002.

  9. Brown J.B. et al., Diabetes Care, 1998, 21 (10), 1659.

  10. Canadian Diabetes Association, Can. J. Diabet., 2008, 32 Suppl. 1.

  11. Chen Y. et al., Proc. Nat. Acad. Sci., 2009, 106 (10), 3907.

  12. Collier A. et al., Diabete Metab., 1989, 15 (6), 420.

  13. Dunn, Peters, Drugs of Today, 1995, 49 (5), 721.

  14. Elliott B.D. et al., Am. J. Obstet. Gynecol., 1994, 171 (3), 653.

  15. Emslie-Smith A.M. et al., Diabet. Med., 2001, 18 (6), 483.

  16. European Medicines Agency - EMA, 2010 comunicato stampa 23 settembre.

  17. European Medicines Agency – EMA, Vipdomet – European public assessment report (EPAR), 2013, 19 settembre.

  18. European Medicines Agency – EMA, Comunicazione EMA/603690/2016, 2016, 14 ottobre, http://www.agenziafarmaco.gov.it/it/content/comunicazione-ema-sui-medicinali-base-di-metformina-14102016 (aceeso: ottobre 2016).

  19. Feig D.S., Ann. Pharmacother., 2007, 41 (7), 1174.

  20. Food and Drug Administration – FDA, Prescribing Information Xigduo, 2014.

  21. Food and Drug Administration – FDA, Safety Alerts for Human Medical Products, Metformin-containing Drugs: Drug Safety Communication - Revised Warnings for Certain Patients With Reduced Kidney Function, 2016, 08 April, http://www.fda.gov/safety/medwatch/safetyinformation/safetyalertsforhumanmedicalproducts/ucm494829.htm (accesso: maggio 2016)

  22. Gin H. et al., Horm. Metab. Res., 1989, 21 (2), 81.

  23. Glueck C.J. et al., Hum. Reprod., 2002, 17 (11), 2858.

  24. Golay A. et al., Diabetes Metab. Rev., 1995, 11 Suppl. 1, S63.

  25. Grant P.J., Diabetes Metab. Rev., 1995, 11 Supll. 1, S43.

  26. Gryer D.R. et al., Diabetes Care, 2005, 28 (3), 539.

  27. Hamann A. et al., Biochem. Biophys. Res. Commun., 1993, 196 (1), 382.

  28. Hamilton et al., Diabetes Care, 2003, 26 (1), 138.

  29. Hansen R.A. et al., Clin. Ther., 2010, 32 (7), 1308.

  30. Hartung D.M. et al., Pharmacotherapy, 2005, 25 (10), 1329.

  31. Holman R.R. et al., NEJM; 2008, 359 (15), 1577.

  32. Holstein A. et al., Diabet. Med., 1999, 16 (8), 692.

  33. Horlen C. et al., JAMA, 2002, 287 (19), 2504.

  34. Ibanez L. et al., J. Clin. Endocrinol. Metab., 2003, 88 (6), 2600.

  35. Johnson et al., Diabetic Med., 2005, 22 (4),, 497.

  36. Jones K. et al., Diabetes Care, 2002, 25 (1), 89.

  37. Klip A., Leiter L.A., Diabetics Care, 1990, 13 (6), 696.

  38. Koc F., Yerdelen D., Neurosciences, 2008, 13 (2), 194.

  39. Lancet, 1998, 352 (9131), 854.

  40. Landin K. et al., J. Intern. Med., 1991, 229 (2), 181.

  41. Lipska K.J. et al., Diabetes Care, 2011, 34 (6), 1431 disponibile on line http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3114336/

  42. Marchetti P. et al., Diabete Metab., 1990, 16 (6), 473.

  43. McIntyre H.D. et al., Aust. N. Z. J. Med., 1991, 21 (5), 714.

  44. Misbin R.T. et al., NEJM, 1998, 338 (4), 265.

  45. Moghetti P, et al., J. Clin. Endocrinol. Metab., 2000, 85 (1), 139.

  46. Nagi D.K. et al., Diabetic Med., 1994, 11 Suppl. 1, 25.

  47. National Health and Medical Research Council, National Evidence based Guideline for Blood Glucose Control in type 2 Diabetes, 2009 disponibile on line http://www.nhmrc.gov.au/guidelines/publications/di19.

  48. National Institute for Health and Clinical Excellence, The Management of Type 2 Diabetes: 2010 NICE Guidelines. London, U.K., 2010.

  49. Ohnhaus E.E. et al., Klin. Wochenscher, 1983, 61 (17), 851.

  50. Ong C.R. et al., Diabetes Care, 2006, 29 (11), 2361.

  51. Pasquali R. et al., J. Clin. Endocrinol. Metab. 2000, 85 (8), 2767.

  52. Prager R. et al., Diabete Metab., 1986, 12 (6), 346.

  53. Rhee M.K et al., Diabetes Educ., 2005, 31 (2), 240.

  54. Riccio A. et al., Diabete Metab., 1991, 17 Suppl. 1, 180.

  55. Rudnichi A. et al., Diabetics, 1994, 43 Suppl. 1, 150A.

  56. Salpeter S.R. et al. Arch. Intern. Med., 2003, 163 (21), 2594.

  57. Sarabia V. et al., J. Clin. Invest., 1992, 90 (4), 1386.

  58. Schectman J.M. et al., Diabetes Care, 2002, 25 (6), 1015.

  59. Scheen A. et al., Eur. J. Clin. Invest., 1994, 24 Suppl.3, 50.

  60. Shlossberg A.H., Can. Fam. Physician., 1993, 39, 119.

  61. Simmons D., Best Pract. Res. Clin. Endocrinol. Metab., 2010, 24 (4), 625.

  62. Società italiana di diabetologia, Standard italiani per la cura del diabete mellito 2009-2010, 2010, 24 novembre.

  63. Somogyi A. et al., Br. J. Clin. Pharmacol., 1987, 23 (5), 545.

  64. Stang M et al., Diabetes care, 1999, 22 (6), 925.

  65. Thomsen H.S. et al., Eur. Radiol., 1999, 9 (4), 738.

  66. Vander T. et al., Diabetic Medicine, 2004, 21 (2), 194.

  67. Wiholm B.E., Myrhed M., Eur. J. Clin. Pharmacol, 1993, 44 (6), 589.